肺腺癌恶性浆膜腔积液:临床病理、分子与结局综合分析
该研究回顾性分析单中心120例细胞学确诊的肺腺癌相关恶性浆膜腔积液病例,整合积液特征、细胞病理、免疫组化、靶向NGS、系统治疗及生存数据。结果显示积液部位、TTF-1及PD-L1状态、可靶向驱动基因改变与生存相关,TTF-1/PD-L1双阴性为最差预后亚组。
要点
- 积液部位影响生存,心包积液OS最短(6.1个月)。
- TTF-1阴性且无可靶向驱动基因是独立不良预后因素。
- TTF-1/PD-L1双阴性亚组SME仅1.2个月、OS仅1.4个月。
核心结论
- 整合细胞学、免疫表型、基因组和治疗可区分肺腺癌恶性浆膜腔积液的不同预后亚组。
- 无可靶向驱动基因改变和TTF-1阴性是独立不良预后因素。
- TTF-1/PD-L1双阴性积液患者SME和OS尤其差。
研究设计与样本
- 单中心回顾性分析120例细胞学确诊的肺腺癌相关恶性浆膜腔积液病例。
- 整合大体积液特征、细胞病理、免疫组化、靶向NGS、系统治疗和临床结局。
- 分析生存指标包括首次恶性积液后生存(SME)和总生存(OS)。
主要发现
- 积液部位:胸膜85/120(70.8%)、心包28/120(23.3%)、腹膜7/120(5.8%)。
- 中位SME为3.8个月,小量腹膜积液亚组最短为1.0个月。
- OS因部位而异,心包受累OS最短为6.1个月。
- TTF-1阳性率为72.5%;PD-L1检测(n=85)TPS≥1%占80%,TPS≥50%占36.5%。
- 分子检测完成111/120(92.5%),TP53突变47/111(42.3%),可靶向驱动改变占42.3%,常见EGFR、KRAS、BRAF、ALK和ROS1。
关键数值与推荐
- TTF-1阳性与更高可靶向驱动改变率和更高PD-L1表达相关。
- PD-L1阴性、TTF-1阴性和无可靶向驱动改变与更短SME和OS相关。
- 双TTF-1/PD-L1阴性亚组中位SME为1.2个月,中位OS为1.4个月。
- 多变量分析证实TTF-1阴性和缺乏可靶向驱动基因独立不良。
- 在接受治疗患者中,免疫治疗方案与最长SME相关(6.7个月),酪氨酸激酶抑制剂方案与最长OS相关(26.0个月)。
临床怎么用
- 对肺腺癌恶性浆膜腔积液应整合细胞学、TTF-1/PD-L1免疫组化和NGS检测。
- TTF-1/PD-L1双阴性或无可靶向驱动基因患者提示预后差,需密切监测和个体化治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Malignant serous effusions (MSEs), including pleural, pericardial, and peritoneal effusions, are common in advanced lung adenocarcinoma (LUAD). However, integrated clinicopathologic, molecular, treatment, and outcome data across effusion sites remain incompletely defined. METHODS: This study retrospectively analyzed 120 cytology-confirmed LUAD-associated MSE cases from a single academic center by integrating gross fluid features, cytopathology, immunohistochemistry, targeted next-generation sequencing (NGS), systemic therapy, and clinical outcomes, including survival from first malignant effusion (SME) and overall survival (OS). RESULTS: Effusions were pleural (85 of 120; 70.8%), pericardial (28 of 120; 23.3%), and peritoneal (7 of 120; 5.8%). Median SME was 3.8 months, and was shortest in the small peritoneal effusion subgroup (1.0 months). OS differed by site, with pericardial involvement showing the shortest OS (6.1 months). Thyroid transcription factor 1 (TTF-1) was positive in 72.5% of cases. Programmed death ligand 1 (PD-L1) testing (n = 85) showed a tumor proportion score (TPS) of ≥1% in 80% of cases and TPS of ≥50% in 36.5% of cases. Molecular profiling was completed in 111 of 120 cases (92.5%) by identifying TP53 mutations in 47 of 111 (42.3%) and actionable driver alterations in 42.3% of cases, most commonly involving EGFR, KRAS, BRAF, ALK, and ROS1. TTF-1 positivity was associated with higher rates of actionable driver alterations and higher PD-L1 expression. PD-L1 negativity, TTF-1 negativity, and an absence of actionable driver alterations were associated with shorter SME and OS. Dual TTF-1/PD-L1 negativity defined the poorest risk subgroup (median SME, 1.2 months; median OS, 1.4 months). Multivariable analysis confirmed that TTF-1 negativity and a lack of actionable drivers remained independently adverse. Among treated patients, immunotherapy-based regimens were associated with the longest SME (6.7 months), whereas tyrosine kinase inhibitor-based therapy was associated with the longest OS (26.0 months). CONCLUSIONS: Integration of cytology, immunophenotype, genomics, and treatment delineates distinct prognostic subsets in LUAD with MSE. The absence of actionable driver alterations and TTF-1 negativity remains an independent adverse prognostic factor, with dual TTF-1/PD-L1-negative MSE showing particularly poor SME and OS.
引用
- Ma W, Li J, Ould Ismail AA, et al. Lung adenocarcinoma with malignant serous effusions: A comprehensive clinicopathologic, molecular, and outcome analysis. Cancer Cytopathol. 2026. PMID: 42145151. doi:10.1002/cncy.70108
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。